REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene....
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome....
Top Cities for Angelman Syndrome Clinical Trials
Angelman Syndrome clinical trials are recruiting across 10 cities. Here are the cities with the most active studies:
About Angelman Syndrome
Angelman syndrome is a rare genetic disorder primarily affecting the nervous system, characterized by severe developmental delays, speech impairment, seizures, and a happy demeanor. It is caused by loss of function of the UBE3A gene. Treatment focuses on managing symptoms and maximizing developmental potential.
Clinical trials are advancing new treatments for angelman syndrome. Currently, 2 studies are recruiting a combined 280 participants across the United States. Research is being conducted by 1 organizations including Ionis Pharmaceuticals, Inc..
2026 Angelman Syndrome Research Landscape
As of March 2026, the angelman syndrome clinical trial landscape includes 2 actively recruiting studies across 10 cities in the United States. These studies are collectively seeking 280 participants, with an average enrollment target of 140 per study.
Research is being led by 1 organization, including Ionis Pharmaceuticals, Inc..
Geographically, angelman syndrome trials are most concentrated in San Diego, California (2 trials); Aurora, Colorado (2 trials); Chicago, Illinois (2 trials); Carrboro, North Carolina (2 trials); Boston, Massachusetts (1 trial) and 5 other cities.
Featured Angelman Syndrome Studies
Highlighted recruiting studies for angelman syndrome, selected by enrollment size and research scope.
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.
Frequently Asked Questions About Angelman Syndrome Clinical Trials
Are there angelman syndrome clinical trials near me?
Yes, there are 2 angelman syndrome clinical trials currently recruiting across 10+ cities in the United States, including San Diego, California; Aurora, Colorado; Chicago, Illinois. Browse the studies above to find one at a location convenient for you.
How do I join a angelman syndrome clinical trial?
To join a angelman syndrome clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are angelman syndrome clinical trials free?
Yes, participation in angelman syndrome clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of angelman syndrome treatments are being studied?
Current angelman syndrome clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 1 research organizations.
Is it safe to participate in angelman syndrome clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 2, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 2, 2026 · Data from ClinicalTrials.gov